Added to YB: 2025-09-09
Pitch date: 2025-09-06
VIMTALABS.NS [neutral]
Vimta Labs Limited
-32.3%
current return
Author Info
No bio for this author
Company Info
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies.
Market Cap
INR 38.9B
Pitch Price
INR 886.95
Price Target
N/A
Dividend
0.11%
EV/EBITDA
29.75
P/E
54.92
EV/Sales
10.51
Sector
Life Sciences Tools and Services
Category
growth
Vimta Labs: From Testing Tables to Billion-Dollar Biologics – The Silent Disruptor in India’s CRO Story
VIMTALABS.NS (overview): Mid-cap CRO transitioning from testing to biologics CRDMO by Q1 FY27, entering $653B global market. Q1 FY26: ₹98Cr revenue (+30% YoY), 35.7% EBITDA margin, ₹19Cr PAT (+36% YoY). Net-debt free with ₹374Cr cash. Mgmt targets doubling turnover in 3yrs. Risk: execution in new vertical.
Read full article (7 min)